Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/10/2019
SIETES contiene 92824 citas

 
 
<< anterior 21 a 40 de 114 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Anónimo. Quetiapine (Seroquel) and QT-interval prolongation. Med Lett Drugs Ther 2011;53:79-80. [Ref.ID 91713]
22.
Mackin P, Thomas SHL. Atypical antipsychotic drugs. BMJ 2011;342:650-4. [Ref.ID 91242]
23. Cita con resumen
Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. A systematic review and meta-analysis. JAMA 2011;306:1359-69. [Ref.ID 91219]
24. Cita con resumen
Lambert T. Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Australian Prescriber 2011;34:97-9. [Ref.ID 91100]
25. Cita con resumen
Devi S. Report criticises antipsychotic use in US nursing homes. Lancet 2011;378:116. [Ref.ID 90864]
26. Cita con resumen
Anónimo. Lurasidone (Latuda) for schizophrenia. Med Lett Drugs Ther 2011;53:13-4. [Ref.ID 90241]
27. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
28.
Frye MA. Bipolar disorder - A focus on depression. N Engl J Med 2011;364:51-9. [Ref.ID 90015]
29. Cita con resumen
Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Landmark CJ. Psychiatric comorbidity in patients with epilepsy: a population-based study. Eur J Clin Pharmacol 2010;66:1151-60. [Ref.ID 89587]
30.Tiene citas relacionadas
Varley C, McClellan J. Risks from antipsychotic medications in children and adolescents. In reply. JAMA 2010;303:730-1. [Ref.ID 87923]
31.Tiene citas relacionadas
Correll CU, Kane JM, Malhotra AK. Risks from antipsychotic medications in children and adolescents. In reply. JAMA 2010;303:730. [Ref.ID 87922]
32.Tiene citas relacionadas Cita con resumen
Lewin AB, Stroch EA, Storch HD. Risks from antipsychotic medications in children and adolescents. JAMA 2010;303:729-30. [Ref.ID 87921]
33.Tiene citas relacionadas Cita con resumen
Mangurian C, Fuentes-Afflick E, Newcomer JW. Risks from antipsychotic medications in children and adolescents. JAMA 2010;303:729. [Ref.ID 87920]
35.Tiene citas relacionadas Cita con resumen
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73. [Ref.ID 86924]
37.
Van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-45. [Ref.ID 86639]
38.Enlace a cita original
39.Enlace a cita original
Carvajal A, García del Pozo J, de Abajo FJ. Utilización de antipsicóticos en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:1-8. [Ref.ID 86458]
40.Enlace a cita original Cita con resumen
Penfold RB, Wang W, Pajer K, Strange B, Kelleher KJ. Spatio-temporal clusters of new psychotropic medications among MIchigan children insured by Medicaid. Pharmacoepidemiol Drug Saf 2009;18:julio. [Ref.ID 86268]
Seleccionar todas
 
<< anterior 21 a 40 de 114 siguiente >>